Mitoxantrone therapy in rapidly worsening multiple sclerosis.
Bratisl Lek Listy
; 106(3): 141-3, 2005.
Article
in En
| MEDLINE
| ID: mdl-16026151
ABSTRACT
BACKGROUND:
This study evaluates mitoxantrone (MX) therapy in patients with relapsing remitting and secondary progressive multiple sclerosis (MS).OBJECTIVES:
Evaluation of the disability progression and side effects of MX.METHODS:
There were studied 33 patients (10 males, 23 females), average age 48.5+/-9.9 SD) with relapsing remitting and secondary progressive MS. The disability was evaluated using Expanded Disability Status Scale (EDSS). Time period from the onset to secondary progressive course of the disease was 9.3 years. Patients, whose disability progression increased by one or more EDSS point per one year, and not responding to other therapy, were treated with mitoxantrone. Patients were treated once monthly with intravenous administration of mitoxantrone 12 mg/m2, not exceeding the maximum cumulative dose of 14 mg/m2 and Solu-Medrol 1000 mg. Six pulses were done in each patient. EDSS score was measured at the beginning of the treatment and after twelwe month. Disability progression was evaluated. Nonparametric Wilcoxon matched pair test was used for statistical analysis. (Tab. 1, Fig. 3, Ref 5.)
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Mitoxantrone
/
Multiple Sclerosis, Chronic Progressive
/
Multiple Sclerosis, Relapsing-Remitting
Limits:
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Bratisl Lek Listy
Year:
2005
Document type:
Article
Affiliation country:
República Checa